A clinical study of 40 women taking tamoxifen starts in April. Recruitment starts now.

This is a collaboration between Karolinska Institutet/hospital, ScientificMed AB and redhot diagnostics AB 

In this joint venture, 40 women that are prescribed tamoxifen will be monitored for four weeks.  Blood samples from the participants will be taken by a nurse at the hospital, as well as by the patients at home where they will use a capillary blood sampling kit, the rhelise™ kit, to take samples by themselves. During these four weeks, patients are also provided with a mobile app from ScientificMed, which is a tool to improve the self-management of the treatment and enable close contact with the healthcare team. Patients can continuously report symptoms and health related data, providing the cancer care team with valuable additional information for better and faster decision making.The advertisement for patient recruitment is only aimed at women in the Stockholm area